Market Overview

Bristol-Myers, Abbott Announce Results from Phase 2 Multiple Myeloma Study

Related BMY
Bristol-Myers Squibb Names Caforio CEO, Andreotti To Become Chairman
10 Biotech Stories You Might've Missed This Week
Apple Leads the Charge as Earnings Season Heats Up (Fox Business)

Squibb Company (NYSE: BMY) and Abbott
(NYSE: ABT) today announced results from a small, randomized Phase 2,
open-label study in patients with previously-treated multiple myeloma
that evaluated two doses of elotuzumab (10 mg/kg and 20 mg/kg) in
combination with lenalidomide and low-dose dexamethasone. In the 10
mg/kg arm, median progression-free survival (PFS), or the time without
disease progression or death, was not reached after 20.8 months of
follow up (N=36) and the objective response rate (ORR) was 92%. Of
patients who received elotuzumab at a dose of 20 mg/kg, median PFS was
18.6 months (N=37) and ORR was 76%.

The safety data are consistent with previously-reported results for

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (ABT + BMY)

Around the Web, We're Loving...

Get Benzinga's Newsletters